Inter- And intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Menzies, Alexander M ^a,b   Haydu, Lauren E ^a,b   Carlino, Matteo S ^a,b,c,d   Azer, Mary W F ^c   Carr, Peter J A ^b,c   Kefford, Richard F ^a,b,c,d   Long, Georgina V ^a,b  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DABRAFENIB; TRAMETINIB;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); TREATMENT RESPONSE;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; GENETIC HETEROGENEITY; HUMANS; MALE; MELANOMA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; TREATMENT OUTCOME;

EID: 84896451505     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085004     Document Type: Article

References (22)

1. Meacham CE, Morrison SJ (2013) Tumour heterogeneity and cancer cell plasticity. Nature 501: 328-337.
2. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, et al. (2013) Cancer genome landscapes. Science 339: 1546-1558.
3. Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, et al. (2012) Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS ONE 7: e29336.
4. Takata M, Morita R, Takehara K (2000) Clonal heterogeneity in sporadic melanomas as revealed by loss-of-heterozygosity analysis. Int J Cancer 85: 492-497. (Pubitemid 30075126)
5. Lin J, Goto Y, Murata H, Sakaizawa K, Uchiyama A, et al. (2011) Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. British Journal of Cancer 104: 464-468.
6. Katona TM, Jones TD, Wang M, Eble JN, Billings SD, et al. (2007) Genetically heterogeneous and clonally unrelated metastases may arise in patients with cutaneous melanoma. Am J Surg Pathol 31: 1029-1037.
7. Wilmott JS, Tembe V, Howle JR, Sharma R, Thompson JF, et al. (2012) Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics 11: 2704-2708.
8. Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501: 346-354.
9. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine 364: 2507-2516.
10. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, et al. (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358-365.
11. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, et al. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New England Journal of Medicine 367: 1694-1703.
12. Kim KB, Flaherty KT, Chapman PB, Sosman JA, Ribas A, et al. (2011) Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM). Journal of Clinical Oncology 29: (abstract 8519).
13. Azer MF, Menzies AM, Haydu LE, Kefford RF, Long GV (2013) Patterns of Response and Progression in Patients with BRAF-mutant Melanoma Metastatic to the Brain treated with Dabrafenib. Cancer: in press.
14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 45: 228-247.
15. McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, et al. (2012) Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. Journal of Clinical Oncology 30: 1628-1634.
16. Carlino MS, Saunders CA, Haydu LE, Menzies AM, Martin Curtis C Jr, et al. (2013) (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. European Journal of Cancer 49: 395-402.
17. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, et al. (2012) Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clinical Cancer Research 18: 1386-1394.
18. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, et al. (2013) BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. Clinical Cancer Research 19: 1225-1231.
19. Chan M, Haydu L, Menzies AM, Azer MWF, Klein O, et al. (2013) Clinical characteristics and survival of BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor dabrafenib or vemurafenib beyond disease progression. Journal of Clinical Oncology 31: (abstract 9062).
20. Ackerman A, Klein O, McDermott DF, Lawrence DP, Gunturi A, et al. (2013) Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer: in press.
21. Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, et al. (2012) Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. Journal of Translational Medicine 10: 107.
22. Carlino MS, Gowrishankar K, Saunders CA, Pupo GM, Snoyman S, et al. (2013) Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Molecular Cancer Therapeutics 12: 1332-1342.